Bioactivity:

Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFR_ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells wh

CAS nr:

796967-16-3

Purity:

98%

Molecular Weight:

375,4

SMILES:

Cc1cc(c(cc1)F)NC(=O)Nc1ccc(cc1)c1c2c(ccc1)[nH]nc2N

Formula:

C21H18FN5O

Pathway:

Angiogenesis,Tyrosine Kinase/Adaptors,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors,Autophagy,Tyrosine Kinase/Adaptors,Apoptosis,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors

Target:

PDGFR,PDGFR,VEGFR,VEGFR,CSF-1R,Autophagy,c-Fms,Apoptosis,c-Kit,FLT,FLT